Tumor lysis syndrome
|Tumor lysis syndrome|
|Classification and external resources|
Tumor lysis syndrome (TLS) is a group of metabolic abnormalities that can occur as a complication during the treatment of cancer, most commonly after the treatment of lymphomas and leukemias. In medicine (oncology and hematology) this is potentially fatal complication, and patients at increased risk for TLS should be closely monitored before, during, and after their course of chemotherapy. Tumor lysis syndrome is characterized by high blood potassium (hyperkalemia), high blood phosphorus (hyperphosphatemia), low blood calcium (hypocalcemia), high blood uric acid (hyperuricemia), and higher than normal levels of blood urea nitrogen (BUN) and other nitrogen containing compounds. These changes in blood electrolytes and metabolites are a result of the release of cellular contents of dying cells into the blood stream from breakdown of cells after cytotoxic therapy or from cancers with high cell turnover and tumor proliferation rates. The metabolic abnormalities seen in tumor lysis syndrome can ultimately result in nausea and vomiting, but more seriously acute uric acid nephropathy, acute kidney failure, seizures, and cardiac arrhythmias.
Signs and symptoms
Hyperkalemia. Potassium is mainly an intracellular ion. High turnover of tumor cells leads to spill of potassium into the blood. Symptoms usually do not manifest until levels are high (> 7 mmol/L) [normal 3.5-5.0 mmol/L] and they include
- cardiac conduction abnormalities (can be fatal)
- severe muscle weakness or paralysis
Hyperphosphatemia. Like potassium, phosphates are also predominantly intracellular. Hyperphosphatemia causes acute kidney failure in tumor lysis syndrome, because of deposition of calcium phosphate crystals in the kidney parenchyma.
- sudden mental incapacity, including emotional lability
- parkinsonian (extrapyramidal) movement disorders
Hyperuricemia and hyperuricosuria. Massive cell death and nuclear breakdown generates large quantities of nucleic acids. Of these, the purines (adenine and guanine) are converted to uric acid via the purine degradation pathway and excreted in the urine. However, at the high concentrations of uric acid generated by tumor lysis, uric acid is apt to precipitate as monosodium urate crystals. Acute uric acid nephropathy (AUAN) due to hyperuricosuria has been a dominant cause of acute kidney failure but with the advent of effective treatments for hyperuricosuria, AUAN has become a less common cause than hyperphosphatemia. Two common conditions related to excess uric acid, gout and uric acid nephrolithiasis, are not features of tumor lysis syndrome.
Pretreatment spontaneous tumor lysis syndrome. This entity is associated with acute kidney failure due to uric acid nephropathy prior to the institution of chemotherapy and is largely associated with lymphomas and leukemias. The important distinction between this syndrome and the post-chemotherapy syndrome is that spontaneous TLS is not associated with hyperphosphatemia. One suggestion for the reason of this is that the high cell turnover rate leads to high uric acid levels through nucleobase turnover but the tumor reuses the released phosphate for growth of new tumor cells. In post-chemotherapy TLS, tumor cells are destroyed and no new tumor cells are being synthesized.
Risk factors for tumor lysis syndrome depend on a several different characteristics of the patient, the type of cancer, and the type of chemotherapy used.
Tumor Characteristics: Tumors with a high cell turnover rate, rapid growth rate, and high tumor bulk tend to be more associated with the development of tumor lysis syndrome. The most common tumors associated with this syndrome are poorly differentiated lymphomas (such as Burkitt's lymphoma), other Non-Hodgkin Lymphomas (NHL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML). Other cancers (such as melanoma) have also been associated with TLS but are less common.
Patient Characteristics: Certain patient-related factors can affect the development of clinical tumor lysis syndrome. These factors include elevated baseline serum creatinine, renal insufficiency, dehydration, and other issues affecting urinary flow or the acidity of urine.
Chemotherapy Characteristics: Chemo-sensitive tumors, such as lymphomas, carry a higher risk for the development of tumor lysis syndrome. Those tumors that are more responsive to a chemotherapy agent carry a higher TLS risk. Usually, the precipitating medication regimen includes combination chemotherapy, but TLS can be triggered in cancer patients by steroid treatment alone, and sometimes without any treatment—in this case the condition is referred to as "spontaneous tumor lysis syndrome".
TLS should be suspected in patients with large tumor burden who develop acute kidney failure along with hyperuricemia (> 15 mg/dL) or hyperphosphatemia (> 8 mg/dL). (Most other acute kidney failure occurs with uric acid < 12 mg/dL and phosphate < 6 mg/dL). Acute uric acid nephropathy is associated with little or no urine output. The urinalysis may show uric acid crystals or amorphous urates. The hypersecretion of uric acid can be detected with a high urine uric acid - creatinine ratio > 1.0, compared to a value of 0.6-0.7 for most other causes of acute kidney failure.
In 2004, Cairo and Bishop defined a classification system for tumor lysis syndrome.
- Laboratory tumor lysis syndrome: abnormality in two or more of the following, occurring within three days before or seven days after chemotherapy.
- uric acid > 8 mg/dL or 25% increase
- potassium > 6 meq/L or 25% increase
- phosphate > 4.5 mg/dL or 25% increase
- calcium < 7 mg/dL or 25% decrease
- Clinical tumor lysis syndrome: laboratory tumor lysis syndrome plus one or more of the following:
- increased serum creatinine (1.5 times upper limit of normal)
- cardiac arrhythmia or sudden death
A grading scale (0-5) is used depending on the presence of lab TLS, serum creatinine, arrhythmias, or seizures.
In 2011, Howard proposed a refinement of the standard Cairo-Bishop definition of TLS accounting for 2 limitations:
- Two or more electrolyte laboratory abnormalities must be present simultaneously to be considered related to TLS. In fact, some patients may present with one abnormality, but later another one may develop that is unrelated to the TLS (e.g., hypocalcemia associated with sepsis).
- A 25% change from baseline should not be considered a criterion since such increases are rarely clinically important unless the value is already outside the normal range.
Moreover, any symptomatic hypocalcemia should constitute clinical TLS.
People about to receive chemotherapy for a cancer with a high cell turnover rate, especially lymphomas and leukemias, should receive prophylactic oral or IV allopurinol (a xanthine oxidase inhibitor, which inhibits uric acid production) as well as adequate IV hydration to maintain high urine output (> 2.5 L/day).
Rasburicase is an alternative to allopurinol and is reserved for people who are high-risk in developing TLS. It is a synthetic urate oxidase enzyme and acts by degrading uric acid. However, it's not clear if it results in any important benefits as of 2014.
Alkalization of the urine with acetazolamide or sodium bicarbonate is controversial. Routine alkalization of urine above pH of 7.0 is not recommended. Alkalization is also not required if uricase is used.
Treatment is first targeted at the specific metabolic disorder.
Acute kidney failure prior to chemotherapy. Since the major cause of acute kidney failure in this setting is uric acid build-up, therapy consists of rasburicase to wash out excessive uric acid crystals as well as a loop diuretic and fluids. Sodium bicarbonate should not be given at this time. If the patient does not respond, hemodialysis may be instituted, which is very efficient in removing uric acid, with plasma uric acid levels falling about 50% with each six hour treatment.
Acute kidney failure after chemotherapy. The major cause of acute kidney failure in this setting is hyperphosphatemia, and the main therapeutic means is hemodialysis. Forms of hemodialysis used include continuous arteriovenous hemodialysis (CAVHD), continuous venovenous hemofiltration (CVVH), or continuous venovenous hemodialysis (CVVHD).
- Davidson MB, Thakkar S, Hix JK, Bhandarkar MD, Wong A, Schreiber MJ (April 2004). "Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome". Am. J. Med. 116 (8): 546–54. doi:10.1016/j.amjmed.2003.09.045. PMID 15063817.
- Niederhuber, John E.; Armitage, James O.; Doroshow, James H.; Kastan, Michael B.; Tepper, Joel E. (2014). Aebeloff's Clinical Oncology, Fifth Edition. Philadelphia: Elsevier Saunders. ISBN 978-1-4557-2865-7.
- Rampello E, Fricia T, Malaguarnera M (August 2006). "The management of tumor lysis syndrome". Nat Clin Pract Oncol 3 (8): 438–47. doi:10.1038/ncponc0581. PMID 16894389.
- A. R. Moossa, Stephen C. Schimpff, Martin C. Robson (1991). Comprehensive textbook of oncology, Volume 2. Lippincott Williams & Wilkins. Retrieved 2 May 2012.
... result in severe metabolic derangements (e.g., hyperuricemia, hypocalcemia, lactic aci- dosis, and the acute tumor lysis syndrome) which require expeditious management. Hyperuricemia Uric acid is the end product of purine catabolism.
- Coiffier, Bertrand; Riouffol, Catherine (2007-02-01). "Management of tumor lysis syndrome in adults". Expert Review of Anticancer Therapy 7 (2): 233–239. doi:10.1586/1473718.104.22.168. ISSN 1473-7140.
- d'Alessandro, V.; Greco, A.; Clemente, C.; Sperandeo, M.; De Cata, A.; Di Micco, C.; Maiello, E.; Vendemiale, G. (2010). "Severe spontaneous acute tumor lysis syndrome and hypoglycemia in patient with germ cell tumor". Tumori 96 (6): 1040–1043. PMID 21388073.
- Cairo MS, Bishop M (October 2004). "Tumour lysis syndrome: new therapeutic strategies and classification". Br. J. Haematol. 127 (1): 3–11. doi:10.1111/j.1365-2141.2004.05094.x. PMID 15384972.
- Howard, SC; Jones, DP; Pui, CH (12 May 2011). "The tumor lysis syndrome.". The New England Journal of Medicine 364 (19): 1844–54. doi:10.1056/NEJMra0904569. PMC 3437249. PMID 21561350.
- Mayne N, Keady S, Thacker M (February 2008). "Rasburicase in the prevention and treatment of tumour lysis syndrome". Intensive Crit Care Nurs 24 (1): 59–62. doi:10.1016/j.iccn.2007.06.002. PMID 17698360.
- Coiffier B, Mounier N, Bologna S, et al. (December 2003). "Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study". J. Clin. Oncol. 21 (23): 4402–6. doi:10.1200/JCO.2003.04.115. PMID 14581437.
- Cammalleri L, Malaguarnera M (2007). "Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout". Int J Med Sci 4 (2): 83–93. doi:10.7150/ijms.4.83. PMC 1838823. PMID 17396159.
- Cheuk, DK; Chiang, AK; Chan, GC; Ha, SY (Aug 14, 2014). "Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.". The Cochrane database of systematic reviews 8: CD006945. doi:10.1002/14651858.CD006945.pub3. PMID 25121561.